The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the thinks below to see and hear what others are saying about the Foundation and our Founder’s story.
Last year marked our 6th year of supporting research into therapies for the treatment of Parkinson’s disease in GBA mutation carriers (GBA-PD). While we transitioned from a public charity to a private foundation in 2023, we were excited to continue our innovative work through several new initiatives.
The Silverstein Foundation Launches Post-Doctoral Fellowship Program to Fund Novel Research for Parkinsons’s Disease in GBA Mutation Carriers
This year marks our 5th year of supporting research into therapies for the treatment of Parkinson’s disease in GBA mutation carriers. We are proud of our many accomplishments and collaborative relationships, which...
Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease
Spurred on by OrbiMed partner’s diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers
The Silverstein Foundation for Parkinson’s with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinson’s disease (PD).
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail’s portfolio of neuroscience assets, and will broaden Lilly’s commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
Prevail Therapeutics Inc. today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, with claims directed to the AAV vector used in PR001, Prevail’s experimental gene therapy program for the treatment of Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD).
Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on neurodegenerative diseases and other related disorders. Chamishi will initially focus on developing antisense oligonucleotide (ASO) therapies for Glucosylceramidase Beta Acid (GBA)-Parkinson’s disease.
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor
Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s, affecting about 10 percent of the more than 6 million people estimated to have the disease. The projects selected through this joint funding program aim to better understand the effect of GBA mutations – and the role of GBA more generally – and advance treatments against this target.
Silverstein Foundation founder, Jonathan Silverstein, named to Forbes Midas List of Top 100 Venture Capitalists for the 7th consecutive year
The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Jointly Announce Availability of $3.5 Million in Fall 2018 Research Funding to Expand Understanding of the GBA gene in Parkinson’s...
Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing. Investors in the round included OrbiMed, Pontifax, RA Capital, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital LLC, Adage Capital Management L.P., and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail.
New York, New York – March 8, 2018 – The Silverstein Foundation for Parkinson’s with GBA and the Michael J. Fox Foundation for Parkinson’s Research today held a joint workshop on accelerating therapeutic development for people with glucocerebrosidase(GBA)-associated Parkinson’s Disease. The meeting was held at the Michael J. Fox Foundation headquarters in New York City.
April, 2017—Two decades of successful investing in some of biotech’s biggest hits has made Jonathan Silverstein rich. Now he is looking for investments that could save his life.
The Michael J. Fox Foundation for Parkinson’s Research: A Personal (and Professional) Mission to Cure Parkinson’s
August, 2017—Health care venture capitalist Jonathan Silverstein has more than two decades of professional experience with strategic investment in drug development. However, Jonathan’s sense of urgency to find cures intensified after he received a...
August, 2017—The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO Inc. (“REGENXBIO”), and OrbiMed today announced the formation and launch of Prevail Therapeutics, Inc., (“Prevail”), a new company focused on discovering and developing novel...
August, 2017—Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson’s disease (PD).
August, 2017—Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to...
CNBC: Venture capitalist wages war against Parkinson’s, searches for miracle after his own diagnosis
August, 2017—It’s been less than a year since Jonathan Silverstein, a venture capitalist at health-care fund OrbiMed, received the diagnosis that changed everything.
The relationship between glucocerebrosidase mutations and Parkinson disease, Migdalska-Richards et. al.
In recent months, Silverstein and his wife, Natalie, set up the Silverstein Foundation, raised $6 million from donors and gave $10 million of their own money to fund half a dozen promising projects and start a new company.